Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma
BMC CANCER (2013)
Journal
BMC CANCER
Volume 13, Issue -, Pages -Publisher
BIOMED CENTRAL LTD
Keywords
Categories
Ask authors/readers for more resources
Authors
I am an author on this paper
Reviews
Recommended
Resistance to BRAF Inhibitors: EZH2 and Its Downstream Targets as Potential Therapeutic Options in Melanoma
Anne Uebel, Stefanie Kewitz-Hempel, Edith Willscher, Kathleen Gebhardt, Cord Sunderkoetter, Dennis Gerloff
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)
Targeted Therapy Given after Anti-PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity
Manali S. Phadke, Zhihua Chen, Jiannong Li, Eslam Mohamed, Michael A. Davies, Inna Smalley, Derek R. Duckett, Vinayak Palve, Brian J. Czerniecki, Peter A. Forsyth, David Noyes, Dennis O. Adeegbe, Zeynep Eroglu, Kimberly T. Nguyen, Kenneth Y. Tsai, Uwe Rix, Christin E. Burd, Yian A. Chen, Paulo C. Rodriguez, Keiran S. M. Smalley
CANCER IMMUNOLOGY RESEARCH (2021)
Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients-Real-World Evidence
Pawel Rogala, Anna M. Czarnecka, Bozena Cybulska-Stopa, Krzysztof Ostaszewski, Karolina Piejko, Marcin Zietek, Robert Dziura, Ewa Rutkowska, Lukasz Galus, Natasza Kempa-Kaminska, Jacek Calik, Agata Salek-Zan, Tomasz Zemelka, Wieslaw Bal, Agnieszka Kamycka, Tomasz Switaj, Grazyna Kaminska-Winciorek, Rafal Suwinski, Jacek Mackiewicz, Piotr Rutkowski
JOURNAL OF CLINICAL MEDICINE (2022)
Kisspeptin-mediated improvement of sensitivity to BRAF inhibitors in vemurafenib-resistant melanoma cells
Carlotta Guzzetti, Cristina Corno, Elisabetta Vergani, Luca Mirra, Emilio Ciusani, Monica Rodolfo, Paola Perego, Giovanni L. Beretta
FRONTIERS IN ONCOLOGY (2023)
Bilirubin Restrains the Anticancer Effect of Vemurafenib on BRAF-Mutant Melanoma Cells Through ERK-MNK1 Signaling
Yufan Tan, Xiaoyu Zhong, Xizhi Wen, Leyi Yao, Zhenlong Shao, Wenshuang Sun, Jiawen Wu, Guanmei Wen, Daolin Tang, Xiaoshi Zhang, Yuning Liao, Jinbao Liu
FRONTIERS IN ONCOLOGY (2021)
High sensitivity sanger sequencing detection of BRAF mutations in metastatic melanoma FFPE tissue specimens
Lauren Y. Cheng, Lauren E. Haydu, Ping Song, Jianyi Nie, Michael T. Tetzlaff, Lawrence N. Kwong, Jeffrey E. Gershenwald, Michael A. Davies, David Yu Zhang
SCIENTIFIC REPORTS (2021)
SPRED1 deletion confers resistance to MAPK inhibition in melanoma
Julien Ablain, Sixue Liu, Gatien Moriceau, Roger S. Lo, Leonard Zon
JOURNAL OF EXPERIMENTAL MEDICINE (2021)
Real-World Experience with Targeted Therapy in BRAF Mutant Advanced Melanoma Patients: Results from a Multicenter Retrospective Observational Study Advanced Melanoma in Russia (Experience) (ADMIRE)
Kristina V. Orlova, Evgeniy V. Ledin, Natalia V. Zhukova, Rashida V. Orlova, Elena V. Karabina, Mikhail V. Volkonskiy, Daniil L. Stroyakovskiy, Aleksandr N. Yurchenkov, Svetlana A. Protsenko, Alexey V. Novik, Ludmila V. Vorotilina, Fedor V. Moiseenko, Victor L. Chang, Aleksandr I. Kazmin, Svetlana A. Tkachenko, Sergey V. Gamaunov, David R. Naskhletashvili, Igor V. Samoylenko, Anastasia S. Vikhrova, Igor A. Utyashev, Galina Yu. Kharkevich, Natalia N. Petenko, Irina Zh. Shubina, Lev V. Demidov
CANCERS (2021)
Inhibition of USP14 enhances anti-tumor effect in vemurafenib-resistant melanoma by regulation of Skp2
Ting Wu, Chengyun Li, Changlong Zhou, Xiaxia Niu, Gege Li, Yali Zhou, Xinsheng Gu, Hongmei Cui
CELL BIOLOGY AND TOXICOLOGY (2023)
Vitamin D Modulates the Response of Patient-Derived Metastatic Melanoma Cells to Anticancer Drugs
Anna Piotrowska, Renata Zaucha, Oliwia Krol, Michal Aleksander Zmijewski
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)
eIF4B enhances ATF4 expression and contributes to cellular adaptation to asparagine limitation in BRAF-mutated A375 melanoma
Yukie Iwao, Yuka Okamoto, Hitomi Shirahama, Satomi Tsukahara, Akihiro Tomida
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2021)
Melanoma Differentiation Trajectories Determine Sensitivity toward Pre-Existing CD8D Tumor
Franziska Noelle Harbers, Beatrice Thier, Simone Stupia, Si Zhu, Marion Schwamborn, Vicky Peller, Heike Chauvistre, Pietro Crivello, Katharina Fleischhauer, Alexander Roesch, Antje Sucker, Dirk Schadendorf, Yong Chen, Annette Paschen, Fang Zhao
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2021)
USP18 enhances the resistance of BRAF-mutated melanoma cells to vemurafenib by stabilizing cGAS expression to induce cell autophagy
Zhou-rui Ma, Qian-wei Xiong, Shi-zhong Cai, Ling-tao Ding, Chao-hong Yin, Hong-liang Xia, Wei Liu, Shu Dai, Yue Zhang, Zhen-hong Zhu, Zhi-jian Huang, Qian Wang, Xiang-ming Yan
INTERNATIONAL IMMUNOPHARMACOLOGY (2023)
Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma
Adi Diab, Scott S. Tykodi, Gregory A. Daniels, Michele Maio, Brendan D. Curti, Karl D. Lewis, Sekwon Jang, Ewa Kalinka, Igor Puzanov, Alexander Spira, Daniel C. Cho, Shanhong Guan, Erika Puente, Tuan Nguyen, Ute Hoch, Sue L. Currie, Wei Lin, Mary A. Tagliaferri, Jonathan Zalevsky, Mario Sznol, Michael E. Hurwitz
JOURNAL OF CLINICAL ONCOLOGY (2021)
Lineage-coupled clonal capture identifies clonal evolution mechanisms and vulnerabilities of BRAFV600E inhibition resistance in melanoma
Ze-Yan Zhang, Yingwen Ding, Ravesanker Ezhilarasan, Tenzin Lhakhang, Qianghu Wang, Jie Yang, Aram S. Modrek, Hua Zhang, Aristotelis Tsirigos, Andrew Futreal, Giulio F. Draetta, Roel G. W. Verhaak, Erik P. Sulman
CELL DISCOVERY (2022)
ASO Visual Abstract: Is a History of Optimal Staging by SLNB in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?
Stephanie A. Blankenstein, Johannes J. Bonenkamp, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Christian U. Blank, Willeke A. M. Blokx, Marye J. Boers-Sonderen, Alfons J. M. van den Eertwegh, Margreet G. Franken, Jan Willem B. de Groot, John B. A. G. Haanen, Geke A. P. Hospers, Ellen W. Kapiteijn, Olivier J. van Not, Djura Piersma, Rozemarijn S. van Rijn, Karijn P. M. Suijkerbuijk, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Hans M. Westgeest, Michel W. J. M. Wouters, Alexander C. J. van Akkooi
ANNALS OF SURGICAL ONCOLOGY (2023)
Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?
Stephanie A. Blankenstein, Johannes J. Bonenkamp, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Christian U. Blank, Willeke A. M. Blokx, Marye J. Boers-Sonderen, Alfons J. M. van den Eertwegh, Margreet G. Franken, Jan Willem B. de Groot, John B. A. G. Haanen, Geke A. P. Hospers, Ellen W. Kapiteijn, Olivier J. van Not, Djura Piersma, Rozemarijn S. van Rijn, Karijn P. M. Suijkerbuijk, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Hans M. Westgeest, Michel W. J. M. Wouters, Alexander C. J. van Akkooi
ANNALS OF SURGICAL ONCOLOGY (2023)
Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study
Monique K. van der Kooij, Arjen Joosse, Karijn P. M. Suijkerbuijk, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Christian U. Blank, Marye J. Boers-Sonderen, Alfonsus J. M. van den Eertwegh, Jan Willem B. de Groot, John B. A. G. Haanen, Geke A. P. Hospers, Djura Piersma, Rozemarijn S. van Rijn, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Hans M. Westgeest, Michel W. J. M. Wouters, Olaf M. Dekkers, Ellen Kapiteijn
BRITISH JOURNAL OF CANCER (2023)
Novel strategies to improve efficacy of treatment with tumor-infiltrating lymphocytes (TILs) for patients with solid cancers
Liselotte Tas, Inge Jedema, John B. A. G. Haanen
CURRENT OPINION IN ONCOLOGY (2023)
γδ T cells are effectors of immunotherapy in cancers with HLA class I defects
Natasja L. de Vries, Joris van de Haar, Vivien Veninga, Myriam Chalabi, Marieke E. Ijsselsteijn, Manon van der Ploeg, Jitske van den Bulk, Dina Ruano, Jose G. van den Berg, John B. Haanen, Laurien J. Zeverijn, Birgit S. Geurts, Gijs F. de Wit, Thomas W. Battaglia, Hans Gelderblom, Henk M. W. Verheul, Ton N. Schumacher, Lodewyk F. A. Wessels, Frits Koning, Noel F. C. C. de Miranda, Emile E. Voest
NATURE (2023)
Identification of patient-specific CD4+ and CD8+ T cell neoantigens through HLA-unbiased genetic screens
Chiara M. M. Cattaneo, Thomas Battaglia, Jos Urbanus, Ziva Moravec, Rhianne Voogd, Rosa de Groot, Koen J. J. Hartemink, John B. A. G. Haanen, Emile E. E. Voest, Ton N. N. Schumacher, Wouter Scheper
NATURE BIOTECHNOLOGY (2023)
Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome Analysis
Melissa M. M. De Meza, Willeke A. M. Blokx, Johannes J. J. Bonenkamp, Christian U. U. Blank, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Marye J. J. Boers-Sonderen, Jan Willem B. De Groot, John B. A. G. Haanen, Geke A. P. Hospers, Ellen Kapiteijn, Olivier J. J. Van Not, Djura Piersma, Rozemarijn S. S. Van Rijn, Marion Stevense-den Boer, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Alfonsus J. M. van den Eertwegh, Karijn P. M. Suijkerbuijk, Michel W. J. M. Wouters
CANCERS (2023)
Exposure-response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients
Stefanie L. Groenland, J. M. Janssen, C. M. Nijenhuis, N. de Vries, H. Rosing, S. Wilgenhof, J. V. van Thienen, J. B. A. G. Haanen, C. U. Blank, J. H. Beijnen, A. D. R. Huitema, N. Steeghs
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2023)
Time interval from primary melanoma to first distant recurrence in relation to patient outcomes in advanced melanoma
Isabella A. J. van Duin, Sjoerd G. Elias, Alfonsus J. M. van den Eertwegh, Jan Willem B. de Groot, Willeke A. M. Blokx, Paul J. van Diest, Tim Leiner, Joost J. C. Verhoeff, Rik J. Verheijden, Olivier J. van Not, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Christian U. Blank, John B. A. G. Haanen, Geke A. P. Hospers, Anna M. Kamphuis, Djura Piersma, Rozemarijn S. van Rijn, Astrid A. M. van Der Veldt, Gerard Vreugdenhil, Michel W. J. M. Wouters, Marion A. M. Stevense-den Boer, Marye J. Boers-Sonderen, Ellen Kapiteijn, Karijn P. M. Suijkerbuijk
INTERNATIONAL JOURNAL OF CANCER (2023)
Adjuvant treatment of in-transit melanoma: Narrowing the knowledge gap left by clinical trials
Melissa M. de Meza, Willeke A. M. Blokx, Han J. Bonenkamp, Cristian U. Blank, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Marye J. Boers-Sonderen, Jan Willem B. de Groot, John B. Haanen, Geke A. P. Hospers, Ellen W. Kapiteijn, Olivier J. van Not, Djura Piersma, Rozemarijn S. van Rijn, Marion A. Stevense-Den A. Boer, Astrid A. M. van Der Veldt, Gerard Vreugdenhil, Alfons J. M. van den Eertwegh, Karijn P. M. Suijkerbuijk, Michel W. J. M. Wouters
INTERNATIONAL JOURNAL OF CANCER (2023)
Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands
Michiel C. T. van Zeijl, Jesper van Breeschoten, Liesbeth C. de Wreede, Michel W. J. M. Wouters, Doranne L. Hilarius, Christian U. Blank, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Jan Willem B. de Groot, Geke A. P. Hospers, Ellen Kapiteijn, Djura Piersma, Rozemarijn S. van Rijn, Marion Stevense-den A. Boer, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Marye J. Boers-Sonderen, Karijn P. M. Suijkerbuijk, John B. A. G. Haanen, Alfons J. M. van den Eertwegh
JOURNAL OF IMMUNOTHERAPY (2023)
Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma
J. B. A. G. Haanen, J. Larkin, T. K. Choueiri, L. Albiges, B. I. Rini, M. B. Atkins, M. Schmidinger, K. Penkov, E. Michelon, J. Wang, M. Mariani, A. di Pietro, R. J. Motzer
ESMO OPEN (2023)
OX40 agonism enhances PD-L1 checkpoint blockade by shifting the cytotoxic T cell differentiation spectrum
Tetje C. van der Sluis, Guillaume Beyrend, Esme T. I. van der Gracht, Tamim Abdelaal, Simon P. Jochems, Robert A. Belderbos, Thomas H. Wesselink, Suzanne van Duikeren, Floortje J. van Haften, Anke Redeker, Laura F. Ouboter, Elham Beyranvand Nejad, Marcel Camps, Kees L. M. C. Franken, Margot M. Linssen, Peter Hohenstein, Noel F. C. C. de Miranda, Hailiang Mei, Adriaan D. Bins, John B. A. G. Haanen, Joachim G. Aerts, Ferry Ossendorp, Ramon Arens
CELL REPORTS MEDICINE (2023)
CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial
Andreas Mackensen, John B. A. G. Haanen, Christian Koenecke, Winfried Alsdorf, Eva Wagner-Drouet, Peter Borchmann, Daniel Heudobler, Barbara Ferstl, Sebastian Klobuch, Carsten Bokemeyer, Alexander Desuki, Florian Lueke, Nadine Kutsch, Fabian Mueller, Eveline Smit, Peter Hillemanns, Panagiotis Karagiannis, Erol Wiegert, Ying He, Thang Ho, Qing Kang-Fortner, Anna Melissa Schlitter, Catrine Schulz-Eying, Andrew Finlayson, Carina Flemmig, Klaus Kuehlcke, Liane Preussner, Benjamin Rengstl, Oezlem Tuereci, Ugur Sahin
NATURE MEDICINE (2023)
BNT211: A Phase I trial to evaluate safety and efficacy of CLDN6 CAR-T cells and CARVac-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumors
John B. A. G. Haanen, Andreas Mackensen, Christian Koenecke, Winfried Alsdorf, Eva Wagner-Drouet, Daniel Heudobler, Peter Borchmann, Carsten Bokemeyer, Sebastian Klobuch, Alexander Desuki, Florian Lueke, Erol Wiegert, Catrine Schulz, Benjamin Rengstl, Liane Preussner, Oezlem Tuereci, Ugur Sahin
CANCER RESEARCH (2022)